A prospective, open-label study was conducted to assess the response to indinavir, efavirenz, and adefovir in human immunodeficiency virus (HIV)-infected patients experiencing viral rebound while receiving therapy with nelfinavir-containing regimens, to determine whether the protease genotype influenced the outcome of the salvage regimen. Genotyping from 29 nelfinavir failures revealed D30N in 17 (59%) and L90M in 11 (38%) cases. Suppression to !400 viral RNA copies/mL was achieved at week 48 in 56% of patients with the D30N virus versus 18% of patients with the L90M virus.
Highly active antiretroviral therapy (HAART) has reduced mortality and morbidity in patients infected with human immunodeficiency virus (HIV) type 1 [1] [2] [3] [4] . These outcomes have been attributed largely to the availability of HIV protease inhibitors (PIs) [5] . However, virological failure eventually occurs in many patients treated with PI-based HAART [6, 7] . Incomplete or transient suppression of HIV replication is a commonly accepted, albeit imperfect, criterion for defining drug failure [1, 7] . Although some patients continue to obtain clinical and immunological benefits, despite detectable circulating HIV RNA [7] , most formal recommendations have advocated changing treatment regimens on the basis of resistance testing when plasma viremia increases [1] . Salvage regimens are generally less effective in achieving and maintaining viral suppression, and recent strategies have focused on choosing initial regimens that can be most consistently rescued [1, [8] [9] [10] . It has been suggested that patients who do not respond to combination therapy containing nelfinavir may respond to different PIs because a common mutation (D30N) in these patients does not confer phenotypic resistance to other PI compounds [9, 11] . As a result of this consideration, nelfinavir is often chosen as the initial PI in antiretroviral regimens [10] . The present study assessed whether the HIV protease genotype in patients who were no longer responding to nelfinavir would affect their virological and immunological responses to a regimen of indinavir, efavirenz, and adefovir.
Materials and methods. Patients were eligible for this openlabel study if they had plasma HIV (v)RNA levels у10 4 copies/ mL and CD4 cell counts у50 cells/mm 3 . Inclusion in the group of patients who transiently responded to nelfinavir ("nelfinavirfailure" group) required an initial у1 log 10 decrease and a subsequent у1 log 10 rebound in plasma vRNA levels after у16 weeks of nelfinavir treatment. Previous use of adefovir, nonnucleoside reverse-transcriptase inhibitors (NNRTIs), or PIs other than nelfinavir were criteria for exclusion. Patients experiencing viral rebound remained on nelfinavir until the first day of the study regimen. All patients received 600 mg of efavirenz once daily, 1000 mg of indinavir every 8 h (as recommended when used with efavirenz [1] ), and 120 mg of adefovir once daily for 8 weeks, followed by 60 mg once daily (with carnitine supplementation). The control group (PI-naive group) included patients who were treatment naive or were not responding to nucleoside reverse-transcriptase inhibitor (NRTI)-only regimens.
Plasma vRNA levels were measured by use of the standard Amplicor reverse-transcriptase polymerase chain reaction (RT-PCR) assay (Roche Molecular Systems), with a lower limit of quantification of 400 copies/mL. Specimens with plasma vRNA levels !400 copies/mL then were assayed by the UltraSensitive assay (Roche Molecular Systems) with a quantification limit of 50 copies/mL. Sequencing of the protease and RT genes was performed as described elsewhere [12] on specimens obtained at entry, while the patient was still receiving nelfinavir. One molecular clone from each of several (typically 8) independent PCRs was sequenced. Amino acid differences from clade B consensus sequences in у2 independent clones were scored as substitutions. Sequences from the patients in this study have been deposited in the GenBank database (accession nos. AY209540-AY209893).
The planned duration of the study was 48 weeks. Primary and secondary outcomes of interest were the virological and immunological responses to the salvage regimen, respectively. Viral suppression was defined as 2 consecutive plasma vRNA 
NOTE.
Amino acid substitutions that differ from the clade B consensus sequence are shown. Dots indicate identity of the residue at that position with the wild-type allele, as identified in the Los Alamos National Laboratory (Los Alamos, NM) databank. Amino acid substitutions associated with reduced susceptibility to indinavir are shown in boldface type. Patients whose last vRNA level was у400 copies/mL are patients 4, 6, 16, 18, 20 
levels !400 copies/mL, as determined by the standard assay. Two consecutive postsuppression values above this level constituted virological failure. Patients with at least 1 vRNA measurement obtained on study therapy who then discontinued the study were subsequently classified as "failures" in the intentto-treat analysis. The proportions of patients in the PI-naive and nelfinavirfailure groups attaining vRNA levels below the limit of quan-tification for each assay were calculated at every scheduled visit. Two patients in the nelfinavir-failure group were excluded from all efficacy analyses because of protocol violations. Group differences were compared by t test for continuous variables and Fisher's exact test for categorical variables. A 2-tailed significance level of , unadjusted for multiple comparisons, P p .05 was applied.
Results. A total of 43 patients (age range, 26-63 years), mostly men (74%), were included in this analysis. Baseline characteristics were similar among the patients in the PI-naive group ( ) and nelfinavir-failure group ( ). At study n p 14 n p 29 entry, viruses from 28 (97%) of the 29 patients in the nelfinavirfailure group carried virus with either the D30N ( ; 59%) n p 17 or the L90M ( ; 38%) protease substitution (table 1) . n p 11 These substitutions were mutually exclusive and were not found in the PI-naive group. D30N was often associated with N88D and/or A71(T/V), whereas L10(I/F), K20(T/I/V/M), M46(I/L), D60E, A71(V/T), G73S, and T74(S/A/P) often were associated with L90M.
The D30N and L90M subgroups did not significantly differ with respect to baseline CD4 cell counts or vRNA levels, number or type of previous NRTI drugs, duration of nelfinavir treatment, time from nadir vRNA level or virological rebound during receipt of nelfinavir to initiation of study drugs, or vRNA levels when nelfinavir was started. Two patients, both with the L90M genotype, discontinued the study because plasma viremia levels were not suppressed. In addition, 4 patients left the study because of adverse experiences (1 PI naive, 1 with D30N, and 2 with L90M). Ten (71%) of 14 patients in the PI-naive group and 20 (69%) of 29 patients in the nelfinavir-failure group (15 [88%] of 17 and 5 [45%] of 11 with D30N and L90M substitutions, respectively) completed the entire 48 weeks of the study.
Substitutions in the RT gene at amino acid residues 41, 62, 65, 67, 70, 74, 75, 115, 116, 118, 151, 184, 210, 215, and 219 were scored as NRTI mutations, and substitutions at residues 100, 103, 106, 108, 181, 188, 190, and 225 were scored as NNRTI mutations [13] . All patients with the D30N or L90M virus substitution had at least 1 NRTI mutation (range, 1-5 mutations); only 1 of these patients had a NNRTI mutation (V106I). No association between the major protease mutation and the number of RT mutations could be demonstrated in this small group of patients. The only patient in the nelfinavirfailure group who did not harbor demonstrable virus with either the D30N or L90M protease substitution had only the K103N resistance mutation in the RT gene.
Baseline vRNA levels and CD4 cell counts were similar among the patients in the PI-naive group (mean, 4.0 log 10 copies/mL; range, 3.6-5.3 log 10 copies/mL; and mean, 339 cells/mm , respectively). Overall, the patients in the nelfinavir-failure group had less decrease in vRNA levels and smaller increases in CD4 cell counts while receiving indinavir, efavirenz, and adefovir than did patients in the PI-naive group, but these differences generally were not statistically significant. There was a smaller decrease in plasma vRNA levels for patients in the nelfinavirfailure group harboring virus with the L90M versus D30N substitutions. The mean increases in CD4 cell counts were essentially superimposable in the 2 nelfinavir-failure subgroups and were less in the nelfinavir-failure group as a whole than in the PInaive group.
The proportions of patients with plasma vRNA levels !400 and !50 vRNA copies/mL were lower in the nelfinavir-failure group than in the PI-naive group, whether analyzed using only observed data or by intent-to-treat analysis. Viremia was suppressed more often in patients not responding to nelfinavir with virus harboring the D30N substitution than in those with virus harboring the L90M substitution, regardless of whether those who discontinued the study were included in the analysis. None of these differences were statistically significant at week 48. In the intent-to-treat analysis that included subjects who did not complete the study as failures, HIV suppression to a plasma vRNA level !400 copies/mL was achieved at week 48 in 8 (57%) of the 14 patients in the PI-naive group (95% confidence interval [CI], 31%-83%) and 11 (39%) of the 28 patients in the nelfinavir-failure group (95% CI, 21%-57%), including 9 (56%) of 16 patients with the D30N virus versus 2 (18%) of 11 patients with L90M virus. Using only the observed data, the corresponding results for both groups were as follows: 8 (80%) of 10 patients in the PI-naive group (95% CI, 55%-100%) and 11 (58%) of 19 patients in the nelfinavirfailure group (95% CI, 36%-80%), including 9 (64%) of 14 patients with the D30N virus versus 2 (40%) of 5 patients with the L90M virus. The percentages of patients in the 3 groups who had vRNA levels !50 copies/mL at week 48 were very similar to the percentages of patients with vRNA levels !400 copies/mL for both the observed data and the intent-to-treat analyses. Patients with the L90M virus tended to achieve and maintain viral suppression less often than did patients with the D30N virus.
Adverse experiences on the triple-combination salvage regimen included asthenia and fatigue (44%), nausea (60%), vomiting (31%), diarrhea (44%), rash (24%), dizziness (36%), upper respiratory tract infection (33%), increased serum cre-atinine levels (47%), hypophosphatemia (53%), and proteinuria (36%). Overall, drug-related clinical and laboratory adverse events occurred in 25 (81%) and 22 (71%), respectively, of 31 patients in the nelfinavir-failure group, compared with 14 (100%) and 9 (64%) of the 14 patients in the PI-naive group. No patient experienced a serious drug-related adverse event. There were 2 serious adverse events not considered to be related to study drugs: cholecystitis/cholelithiasis and erythema multiforme minor. In total, 5 patients (11%) left the study because of drug-related adverse experiences, including gastrointestinal complaints in 2 patients and a pruritic rash, elevated serum creatinine level, and electrolyte abnormalities with proteinuria in 1 patient each.
Discussion. In this small cohort of patients who experienced viral rebound while receiving nelfinavir, resistance mutations in the protease gene evolved along 2 mutually exclusive pathways characterized by the presence of either the D30N or the L90M amino acid substitutions [14] . Each of these genotypes was accompanied by additional substitutions in the protease and RT genes. The D30N and L90M genotypes were associated with differing virological responses to the indinavir-containing salvage regimen [13, 15] . Virological response rates for patients harboring virus with the D30N substitution were similar to those for patients in the PI-naive group and were higher than rates for patients with the L90M virus. Patients in both nelfinavir-failure subgroups had similar increases in CD4 cell counts, which were lower than those seen in patients in the PI-naive group. Because all of our patients were adefovir and NNRTI naive, the response to the combination salvage regimen administered in this study probably was influenced by the use of efavirenz and adefovir in addition to indinavir.
This unblinded exploratory study has several limitations. This trial was not powered to confidently exclude true differences between groups on the basis of a failure to demonstrate significant differences. With the small number of enrolled patients, only large differences could achieve statistical significance. Our efficacy analysis primarily considered substitutions in the protease gene and their associations with surrogate markers. The HIV-protease resistance pattern in patients who transiently respond to nelfinavir may depend on the infecting HIV subtype [16, 17] . For the patients in the nelfinavir-failure group, CD4 cell counts before treatment with nelfinavir were not available. CD4 cell counts at entry to our study probably were still elevated relative to pretreatment levels in patients who had received nelfinavir, despite virological failure [7] ; therefore, the smaller increase in CD4 cell counts in these patients, compared with that in patients in the PI-naive group, is not surprising. All patients received the same salvage regimen containing at least 1 new drug class and 3 new drugs. The combination therapy used in this study is obsolete, and response rates may be substantially different with more contemporary regimens (e.g., ritonavir-enhanced PI salvage regimens) [1, 9] . Nonetheless, indinavir in combination with a nucleoside and an NNRTI can suppress viremia at least for the short-term in some patients for whom nelfinavir-based therapy has recently failed.
The L90M substitution may blunt the virological response to a subsequent PI-containing regimen [14, 15] . We found the L90M substitution in virus from 38% of our patients who were not responding to nelfinavir when they were still receiving this drug, which is a higher prevalence than previously reported elsewhere [11] . Kempf et al. [18] recently identified protease resistance mutations in 31 (29%) of 106 patients who had detectable viremia while receiving a nelfinavir-based regimen for 24-48 weeks; 8 (26%) of 31 patients had virus with the L90M substitution. The length of exposure to nelfinavir and the RT inhibitors in the regimens differed between studies. Furthermore, the multiple-clone-sequencing method used in our study is potentially more sensitive in detecting low-frequency variants than the standard population-sequencing method [19] . Four of our patients carried virus with the L90M substitution as minor populations (2-3 independent clones/ patient, representing 12%-30% of circulating virus) that may not be reliably detected by population sequencing.
